Neuronetics Inc (STIM) Expected to Post Quarterly Sales of $12.68 Million

Wall Street brokerages expect that Neuronetics Inc (NASDAQ:STIM) will announce sales of $12.68 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Neuronetics’ earnings. The lowest sales estimate is $12.65 million and the highest is $12.70 million. The firm is scheduled to announce its next earnings results on Tuesday, November 13th.

On average, analysts expect that Neuronetics will report full-year sales of $50.73 million for the current financial year, with estimates ranging from $50.65 million to $50.80 million. For the next fiscal year, analysts expect that the company will post sales of $61.11 million, with estimates ranging from $60.70 million to $61.52 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Neuronetics.

Neuronetics (NASDAQ:STIM) last announced its quarterly earnings data on Tuesday, August 14th. The company reported ($30.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($29.76). The company had revenue of $13.25 million during the quarter, compared to analyst estimates of $12.20 million.

Several analysts recently issued reports on STIM shares. William Blair started coverage on Neuronetics in a report on Monday, July 23rd. They set an “outperform” rating for the company. Canaccord Genuity started coverage on Neuronetics in a report on Tuesday, July 24th. They set a “buy” rating and a $33.00 price objective for the company. Piper Jaffray Companies started coverage on Neuronetics in a report on Monday, July 23rd. They set an “overweight” rating for the company. JMP Securities increased their price objective on Neuronetics from $36.00 to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, August 15th. Finally, BTIG Research reiterated a “buy” rating and set a $33.00 price objective on shares of Neuronetics in a report on Thursday, August 16th. Five equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average target price of $36.33.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Emerald Mutual Fund Advisers Trust bought a new position in Neuronetics during the second quarter valued at about $1,570,000. Granahan Investment Management Inc. MA bought a new position in Neuronetics during the second quarter valued at about $266,000. Wells Fargo & Company MN bought a new position in Neuronetics during the second quarter valued at about $7,734,000. Peregrine Capital Management LLC bought a new position in Neuronetics during the second quarter valued at about $4,659,000. Finally, RTW Investments LP bought a new position in Neuronetics during the second quarter valued at about $5,056,000. Institutional investors own 62.32% of the company’s stock.

Shares of NASDAQ:STIM opened at $22.47 on Thursday. The company has a current ratio of 1.75, a quick ratio of 1.59 and a debt-to-equity ratio of -0.13. Neuronetics has a 1 year low of $20.70 and a 1 year high of $39.39.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood.

Recommended Story: Growth Stocks

Get a free copy of the Zacks research report on Neuronetics (STIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply